Form4insider filings, from the source

SEC Form 3 · accession 0001209191-16-132670

Orexigen Therapeutics, Inc. · OREXQ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Peter D Flynn
Officer — SVP, Dev, Reg Affairs, Safety
Period of report
Jun 8, 2016
Accepted (ET)
Jul 14, 2016 · 2:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———1,236D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionF1$6.04holding————Feb 22, 2025Common Stock125,000—D
Stock OptionF1$1.78holding————Feb 1, 2026Common Stock105,000—D
Performance Stock UnitsF2$0.00holding————Feb 1, 2021Common Stock90,000—D

Explanation of responses